Thoracic Mobilization for Restrictive Lung Disease
ConditionRestrictive Lung Disease
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age19+
SponsorChungnam National University Sejong Hospital
About this trial
This study aims to investigate the immediate effects of thoracic mobilization techniques on cough capacity, dyspnea, and pulmonary function in patients with restrictive lung disease. The intervention will be applied in a single session, and outcomes will be measured before and after the intervention to evaluate short-term physiological changes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 19 years or older
Currently receiving respiratory therapy at C Hospital in Sejong City
Pulmonary function test indicating restrictive pattern: FVC < 80% and FEV1/FVC ≥ 70%
FVC above the lower limit of normal (LLN) for age and sex
Disqualifiers
FEV1/FVC ratio < 70%
Evidence of airway obstruction on pulmonary function testing
Trial design
Design model
Parallel
Treatments tested in this trial
Thoracic mobilization
Other interventionParticipants in this group will receive thoracic mobilization techniques in addition to conventional respiratory therapy. Thoracic mobilization will be delivered by a licensed physical therapist using passive manual techniques targeting the thoracic spine and rib cage to improve chest wall mobility and respiratory function.
conventional therapy
Other interventionParticipants in this group will receive conventional respiratory therapy, including diaphragmatic breathing, pursed-lip breathing, and chest expansion exercises. The therapy will be administered by a licensed physical therapist following standard pulmonary rehabilitation protocols.
Treatment groups
24 Participants
are divided into 2 treatment groupsGroup A: Thoracic mobilization groupExperimental treatment 2 interventions
Group B: conventional therapy groupActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Pulmonary function test
Pulmonary function will be assessed using a standard spirometry test, including FVC and FEV1. The test will be conducted by a trained technician according to ATS/ERS guidelines to evaluate respiratory function.
Time frame
Immediately before and immediately after intervention on Day 1Secondary outcomes
1
Cough peak flow
Cough peak flow will be measured using a peak flow meter. Participants will be instructed to perform a maximal voluntary cough following a deep inspiration, and the highest value from three trials will be recorded. The assessment will be conducted by a trained therapist to evaluate cough capacity.
Time frame
Immediately before and immediately after intervention on Day 12
Dyspnea
Dyspnea will be assessed using the modified Borg scale, a subjective rating scale ranging from 0 (no breathlessness) to 10 (maximum breathlessness). Participants will rate their perceived level of dyspnea at rest following the intervention. The assessment will be administered by a trained therapist.
Time frame
Immediately before and immediately after intervention on Day 1Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: